#BioMarin

Thiard News@F4F

@newsen.bsky.social

3 days ago

BioMarin's VOXZOGO Shows Positive Growth Outcomes for Children with Achondroplasia BioMarin Pharmaceuticals shares new data on the effectiveness of VOXZOGO in promoting growth in children with achondroplasia, demonstrating significant early treatment benefits.

BioMarin's VOXZOGO Shows Positive Growth Outcomes for Children with Achondroplasia #United_States #San_Rafael #BioMarin #VOXZOGO #achondroplasia

Thiard News@F4F

@newsen.bsky.social

3 days ago

New Research in Genomics Reveals Insights into Rare Genetic Disorders Underdiagnosis Recent findings presented at the ACMG meeting spotlight the underdiagnosis of rare genetic disorders, enhancing access to treatment options for affected patients.

New Research in Genomics Reveals Insights into Rare Genetic Disorders Underdiagnosis #Genomics #Genetic_Disorders #BioMarin

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

BioMarin's PALYNZIQ Receives FDA Approval for Adolescents with PKU The FDA has approved BioMarin's PALYNZIQ for adolescents aged 12 and up, providing a crucial treatment option for individuals with phenylketonuria (PKU).

BioMarin's PALYNZIQ Receives FDA Approval for Adolescents with PKU #United_States #San_Rafael #BioMarin #PKU #PALYNZIQ

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

BioMarin Pharmaceutical Inc. Reports Significant Growth in Revenues and Plans for 2026 Acquisitions BioMarin Pharmaceutical Inc. showcased an impressive revenue growth for 2025 and announced future acquisition plans that could elevate its market position significantly.

BioMarin Pharmaceutical Inc. Reports Significant Growth in Revenues and Plans for 2026 Acquisitions #USA #San_Rafael #BioMarin #VOXZOGO #Amicus_Therapeutics

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Phenylketonuria Market Set to Thrive by 2034 with New Therapies and Increased Awareness The Phenylketonuria market is projected to see significant growth by 2034, driven by novel therapies and rising awareness. Advances in treatment are enhancing patient lives.

Phenylketonuria Market Set to Thrive by 2034 with New Therapies and Increased Awareness #None #BioMarin #PKU #Phenylketonuria

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioMarin Completes Pricing of Senior Notes and New Loan Facility for Amicus Acquisition BioMarin Pharmaceutical announces the pricing of $850 million in senior unsecured notes and a $2 billion term loan to fund its Amicus acquisition.

BioMarin Completes Pricing of Senior Notes and New Loan Facility for Amicus Acquisition #BioMarin #BMRN #Amicus

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioMarin Unveils Plans for $850 Million Senior Note Offering and $2 Billion Secured Loan BioMarin Pharmaceutical Inc. has announced a proposed $850 million offering of senior notes and a $2 billion secured term loan as part of its acquisition strategy.

BioMarin Unveils Plans for $850 Million Senior Note Offering and $2 Billion Secured Loan #United_States #Senior_Notes #San_Rafael #BioMarin #Amicus_Therapeutics

Thiard News@F4F

@newsen.bsky.social

2 months ago

BioMarin Welcomes Arpit Davé as New Chief Digital and Information Officer BioMarin Pharmaceutical Inc. has named Arpit Davé the Chief Digital and Information Officer, emphasizing innovation in patient care.

BioMarin Welcomes Arpit Davé as New Chief Digital and Information Officer #United_States #San_Rafael #biotechnology #BioMarin #Arpit_Davé

Thiard News@F4F

@newsen.bsky.social

2 months ago

BioMarin's Key Announcement at the Upcoming J.P. Morgan Healthcare Conference BioMarin Pharmaceutical will present at the J.P. Morgan Healthcare Conference. CEO Alexander Hardy is set to talk about their latest financial results.

BioMarin's Key Announcement at the Upcoming J.P. Morgan Healthcare Conference #United_States #San_Francisco #J.P._Morgan #BioMarin #Alexander_Hardy

Thiard News@F4F

@newsen.bsky.social

2 months ago

Veeva Systems and BioMarin Form Strategic Long-Term Partnership for Innovative Therapies Veeva Systems and BioMarin have announced a long-term strategic partnership aimed at enhancing the speed and efficiency of developing innovative therapies.

Veeva Systems and BioMarin Form Strategic Long-Term Partnership for Innovative Therapies #USA #Veeva_Systems #biotechnology #Pleasanton #BioMarin

Thiard News@F4F

@newsen.bsky.social

2 months ago

Veeva and BioMarin Strengthen Collaboration for Drug Development and Commercialization Veeva Systems and BioMarin Pharmaceutical have announced a long-term strategic partnership aimed at enhancing the efficiency of innovative therapies.

Veeva and BioMarin Strengthen Collaboration for Drug Development and Commercialization #USA #Veeva_Systems #San_Rafael #BioMarin #Therapy_Development

Thiard News@F4F

@newsen.bsky.social

4 months ago

FDA Grants Priority Review for BioMarin's PALYNZIQ Application to Treat Adolescents with PKU BioMarin's PALYNZIQ has received FDA's Priority Review status to extend its use in treating adolescents aged 12-17 with phenylketonuria.

FDA Grants Priority Review for BioMarin's PALYNZIQ Application to Treat Adolescents with PKU #United_States #San_Rafael #BioMarin #PKU #PALYNZIQ

Thiard News@F4F

@newsen.bsky.social

6 months ago

BioMarin Presents Groundbreaking Data on Bone Health Improvement at ASBMR 2025 At ASBMR 2025, BioMarin highlights key findings from 14 studies showcasing VOXZOGO's impact on spinal morphology and growth in children with achondroplasia.

BioMarin Presents Groundbreaking Data on Bone Health Improvement at ASBMR 2025 #USA #Seattle,_Washington #BioMarin #Bone_Health #VOXZOGO

Thiard News@F4F

@newsen.bsky.social

6 months ago

BioMarin's PALYNZIQ Shows Efficacy in Phase 3 Study for PKU Adolescents at ICIEM BioMarin Pharmaceutical shares promising Phase 3 data for PALYNZIQ, showing significant efficacy in lowering blood Phe levels among adolescents with PKU.

BioMarin's PALYNZIQ Shows Efficacy in Phase 3 Study for PKU Adolescents at ICIEM #USA #San_Rafael #BioMarin #PALYNZIQ #Phenylketonuria

Thiard News@F4F

@newsen.bsky.social

6 months ago

BioMarin Pharmaceutical Announces Key Participation in September Investor Conferences BioMarin Pharmaceutical is set to present at several key investor conferences in September, highlighting their innovative therapies and pipeline.

BioMarin Pharmaceutical Announces Key Participation in September Investor Conferences #United_States #San_Rafael #biotechnology #BioMarin #BMRN

Mandeville GemsSeller GIA AJP

@gemsseller.bsky.social

6 months ago

Just in case y'all think thing are great in the work world. Client 66 yr old gal worked for #BioMarin for 17 yrs. Just fired, no cause, then very young person hired to replace her/started the day they fired her. She has repeated stellar reviews as recent as 3 months ago.lost benefits,needs to work

Thiard News@F4F

@newsen.bsky.social

7 months ago

BioMarin Highlights Impressive Second Quarter 2025 Earnings and Plans Ahead for Growth BioMarin Pharmaceutical Inc. reports significant revenue growth in Q2 2025, raising full-year guidance. New therapies and acquisitions contribute to strong pipeline progress.

BioMarin Highlights Impressive Second Quarter 2025 Earnings and Plans Ahead for Growth #USA #San_Rafael #BioMarin #VOXZOGO #BMN_333

Thiard News@F4F

@newsen.bsky.social

7 months ago

BioMarin Appoints Ian T. Clark to Board of Directors Enhancing Leadership Team BioMarin Pharmaceutical has appointed Ian T. Clark to its Board of Directors, bringing extensive biopharmaceutical experience to the team.

BioMarin Appoints Ian T. Clark to Board of Directors Enhancing Leadership Team #United_States #San_Rafael #Board_of_Directors #BioMarin #Ian_Clark

Thiard News@F4F

@newsen.bsky.social

8 months ago

BioMarin Completes Acquisition of Inozyme Pharma to Enhance Enzyme Therapies BioMarin Pharmaceutical has finalized its acquisition of Inozyme Pharma for $270 million, boosting its enzyme therapy portfolio significantly.

BioMarin Completes Acquisition of Inozyme Pharma to Enhance Enzyme Therapies #United_States #San_Rafael #BioMarin #Inozyme #ENPP1_Deficiency

Thiard News@F4F

@newsen.bsky.social

9 months ago

Monteverde & Associates PC Investigates Inozyme Pharma Merger with BioMarin Monteverde & Associates PC initiates an investigation into the merger between Inozyme Pharma and BioMarin, focusing on shareholder interests.

Monteverde & Associates PC Investigates Inozyme Pharma Merger with BioMarin #United_States #New_York #Monteverde_Associates #BioMarin #Inozyme_Pharma

Thiard News@F4F

@newsen.bsky.social

10 months ago

BioMarin Showcases Promising VOXZOGO Data at Key Endocrinology Meetings BioMarin Pharmaceutical has announced encouraging findings for VOXZOGO, showcasing its benefits in children with achondroplasia and other skeletal conditions at international endocrinology events.

BioMarin Showcases Promising VOXZOGO Data at Key Endocrinology Meetings #USA #San_Rafael #BioMarin #VOXZOGO #achondroplasia

Thiard News@F4F

@newsen.bsky.social

10 months ago

BioMarin Pharmaceuticals Delivers Strong Q1 Results and Maintains Full-Year Projections for 2025 BioMarin Pharmaceutical Inc. reported substantial financial gains in Q1 2025, reaffirming its full-year guidance with a strong outlook for growth and innovative therapy launches.

BioMarin Pharmaceuticals Delivers Strong Q1 Results and Maintains Full-Year Projections for 2025 #United_States #San_Rafael #BioMarin #VOXZOGO #PALYNZIQ

pharmaphorum

@pharmaphorum.bsky.social

10 months ago

Spruce Bio sows the seeds of its new future Spruce has bounced back from the failure of its lead drug last year, thanks to a licensing deal with BioMarin for a late-stage Sanfilippo drug.

NEWS: #SpruceBiosciences' future was in doubt when it dropped its lead drug for congenital adrenal hyperplasia in December, but has now charted a way forward – thanks to a #licensingdeal with #BioMarin.

pharmaphorum.com/news/spruce-...

Thiard News@F4F

@newsen.bsky.social

11 months ago

BioMarin Unveils Promising Data on VOXZOGO for Young Children with Achondroplasia at ACMG 2025 At the 2025 ACMG Annual Clinical Genetics Meeting, BioMarin revealed promising data for VOXZOGO in children with achondroplasia, emphasizing safety and adherence.

BioMarin Unveils Promising Data on VOXZOGO for Young Children with Achondroplasia at ACMG 2025 #United_States #Los_Angeles #BioMarin #VOXZOGO #achondroplasia

Thiard News@F4F

@newsen.bsky.social

1 year ago

BioMarin Pharmaceutical Welcomes Timothy P. Walbert to Its Board of Directors BioMarin Pharmaceutical Inc. has appointed Timothy P. Walbert to its Board of Directors, aiming for enhanced operational expertise and patient-centered strategies.

BioMarin Pharmaceutical Welcomes Timothy P. Walbert to Its Board of Directors #USA #San_Rafael #board_appointment #BioMarin #Timothy_Walbert

Thiard News@F4F

@newsen.bsky.social

1 year ago

BioMarin Takes Legal Action Against Ascendis Pharma Over Patent Rights in Europe BioMarin Pharmaceutical Inc. initiates legal proceedings against Ascendis Pharma A/S for alleged infringement of its European patent concerning C-Type Natriuretic Peptide variants.

BioMarin Takes Legal Action Against Ascendis Pharma Over Patent Rights in Europe #United_States #San_Rafael #Ascendis_Pharma #BioMarin #CNP

Thiard News@F4F

@newsen.bsky.social

1 year ago

BioMarin to Showcase Innovations at Upcoming J.P. Morgan Conference in San Francisco BioMarin Pharmaceutical Inc. is set to present at the 43rd J.P. Morgan Healthcare Conference in January, showcasing their advancements in biotechnology.

BioMarin to Showcase Innovations at Upcoming J.P. Morgan Conference in San Francisco #United_States #San_Francisco #J.P._Morgan #biotechnology #BioMarin

Angela

@bluecollardaughter.bsky.social

12 years ago

"@JadeCSheppard #BioMarin please approve @andi_sloan for BMN673 to fight rare cancer. cleared for compassionate need.”"